FIGS · FIGS

The thesis

FIGS shares hold a modest edge over the S&P 500 because the company beat third-quarter estimates and raised its 2026 outlook on 5 November 2026. Earnings Whispers counted it as the fourth straight call with a raised full-year outlook. The fourth-quarter report, expected in late February 2027, settles whether the roughly 15% growth guide holds through what management calls the worst of the Jordan import block.

Third-quarter revenue was $190.7 million, up 25.7% year over year, per the company's 8-K. Diluted earnings per share (EPS) were $0.10 against a $0.07 estimate cited by Benzinga. The company lifted its 2026 revenue-growth outlook to about 23.5% from about 20%. It also raised its adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) margin outlook to about 15.8% from 14.8%–15.0%.

Executives sold stock into the rally. Chief Executive Catherine "Trina" Spear exercised 8,595,000 options at an average $0.90 on 9 November 2026, according to her SEC Form 4. On the same day 4,550,716 shares were withheld for tax at $21.58 and 4,044,284 were sold on the open market at $19.70. MarketBeat valued the sale at $79.7 million. Chief Financial Officer Sarah Oughtred sold 90,000 shares at $21.92 on 11 November 2026, per her Form 4. The rating is Medium because the raised guide and fresh broker coverage carry more weight than the selling, which followed the exercise of options priced near $1.

The price already reflects the raised outlook. The shares closed at $22.68 on 12 November 2026, above the $21.14 average analyst target MarketBeat reported on 9 November 2026. Further gains depend on targets continuing to rise or on holiday sales beating the fourth-quarter guide.

Bullish and bearish views on FIGS, Inc.

The bull case on FIGS, Inc. (FIGS), in brief: revenue beat every published estimate. The bear case: the chief executive sold heavily.

Bull case

• Revenue beat every published estimate. The $190.7 million reported on 5 November 2026 topped Benzinga's $180.2 million and FactSet's $182.8 million consensus figures.
• Guidance sits well above consensus. On 5 November 2026 Benzinga put the fourth-quarter revenue guide at $232.18 million against a $221.73 million estimate, and the full-year guide at $779.41 million against $758.69 million.
• Customers and spending both grew. Active customers rose 14.3% to about 3.2 million and net revenue per active customer rose 12.9% to $236, per the 5 November 2026 release. Average order value rose 10.5% to $126.
• International is growing quickly. International revenue rose 51.4% to $36.8 million in the third quarter, per the release. On the 5 November 2026 call, management said every international market is profitable.
• Profit is scaling and cash is building. Adjusted EBITDA margin reached 16.5%, against 12.4% a year earlier, per the release. Nine-month free cash flow was $89.8 million, against negative $5.1 million a year earlier.
• Broker coverage keeps widening. Cantor Fitzgerald started coverage on 10 November 2026 with an Overweight rating and a $25 target, per Benzinga. Barclays ($28) and KeyBanc ($27) raised their targets on 6 November 2026, after Oppenheimer and BTIG each moved to $25 on 29 October 2026 and 30 October 2026.

Bear case

• The chief executive sold heavily. Spear's 9 November 2026 Form 4 shows that the shares withheld and the shares sold together account for all 8,595,000 options she exercised. MarketBeat reported her direct holding at 1,671,854 shares after the sale.
• The CFO sold in the open market. Oughtred's 90,000-share sale at $21.92 on 11 November 2026 came two sessions after the chief executive's sale. Earlier dispositions by Oughtred on 1 October 2026 and 2 November 2026 were tax-withholding transactions.
• Growth is guided to slow sharply. The fourth-quarter guide is about 15%, against 25.7% in the third quarter. Oughtred called the quarter "heavily back-weighted" on the 5 November 2026 call, so the result depends on late-quarter holiday sales.
• The Jordan block has not peaked. Spear said on the 5 November 2026 call that the fourth quarter takes the worst of the US Customs Withhold Release Order, with effects running through the second quarter of 2027. Inventory was $121.3 million at 30 September 2026, down 20% year over year.
• Gross margin carries one-time refunds. Third-quarter gross margin fell 0.6 percentage point to 69.3%, per the release. Earnings Whispers reported on 5 November 2026 that about 2.5 percentage points of 2026 gross margin come from one-time tariff refunds, and that the CFO framed normalized 2027 gross margin near 67.5%.
• The price is above the average target. The $22.68 close on 12 November 2026 sits above MarketBeat's $21.14 average target from 9 November 2026 and the $25 targets from Cantor, Oppenheimer and BTIG are close by. Only Barclays ($28) and KeyBanc ($27) are materially higher.

Price setup

The shares closed at $22.68 on 12 November 2026. That is 4.6% below the 52-week intraday high of $23.77 set on 11 November 2026, a session that closed at $23.40. The 3-month price change is 54.4%, measured from the $14.69 close on 14 August 2026. The 52-week closing low was $9.11 on 18 November 2025.

The reaction to the report came in two steps. The close fell from $20.21 on 5 November 2026 to $19.82 on 6 November 2026. The shares then rose to $21.58 on 9 November 2026, $22.39 on 10 November 2026 and $23.40 on 11 November 2026, despite the chief executive's sale on 9 November 2026.

In adjusted daily closes, the shares trade well above both moving averages. The 50-day moving average is $16.93 and the 200-day moving average is $13.90, both as of 12 November 2026. No company results are due until late February 2027, so the holiday-season sales commentary and insider filings are the main new information before then.

Catalysts ahead

• ~24 November 2026 (est.): Short-interest publication for the mid-November settlement. Shows whether short sellers covered or added after the third-quarter results, the executive sales and the move to a 52-week high.
• 27 November 2026: Black Friday opens the peak holiday weeks, with Cyber Monday on 30 November 2026. Management called the fourth quarter heavily back-weighted, and in-stock levels are still recovering from the Jordan transition.
• ~25 February 2027 (est.): Fourth-quarter 2026 report. Tests the roughly 15% growth guide and the gross-margin path, and gives the first 2027 outlook with tariff refunds out of the comparison.

What would change the view

A daily close below $18.00, the 13 October 2026 close, which would erase the advance since mid-October. Fourth-quarter revenue growth under the roughly 15% guide, or a cut to the about 23.5% 2026 growth or about 15.8% adjusted EBITDA margin outlook, would also show the case failing.

The risks this note tracks, each with what would confirm it:

• The Jordan transition hurts sales more than management built into its fourth-quarter guide. Confirmed by: fourth-quarter revenue growth under about 15%, or management extending Jordan-related effects past the second quarter of 2027.
• Growth slows beyond the supply effect as comparisons toughen. Confirmed by: active-customer growth well below the 14.3% reported for the third quarter, or a 2027 revenue outlook that does not reaccelerate as inventory rebuilds.
• Gross margin falls in 2027 as tariff refunds drop out and Vietnam sourcing carries higher duty and fabric costs. Confirmed by: a 2027 gross-margin outlook below the roughly 67.5% normalized rate cited on 5 November 2026.
• Executive selling continues, signalling that management sees the shares as fully valued. Confirmed by: further open-market Form 4 sales by the CEO, CFO or executive chair, outside tax withholding, before the fourth-quarter report.
• Analyst targets stop rising with the shares above the average target. Confirmed by: downgrades or unchanged targets from Barclays, KeyBanc, Cantor, Oppenheimer or BTIG while the shares trade above $25.
• Demand weakens as healthcare hiring slows. Confirmed by: consecutive monthly Bureau of Labor Statistics jobs reports showing smaller healthcare payroll gains, alongside slower active-customer growth at the next report.

What it trades with

FIGS trades mainly on its own quarterly results and guidance. Its demand follows healthcare employment more than general consumer spending, because most buyers are working healthcare professionals. Slower healthcare payroll growth in Bureau of Labor Statistics jobs reports would be the macro signal to watch. The second exposure is US tariff and customs policy. 2026 gross margin includes refunds of tariffs paid under the International Emergency Economic Powers Act (IEEPA), and the Customs import block on the company's Jordan supplier shapes fourth-quarter sales. A change in either policy moves the margin outlook directly.